UPDATE: H.C. Wainwright Starts Oncolytics Biotech (ONCY) at Buy, $15 PT

February 17, 2021 6:15 AM EST
Get Alerts ONCY Hot Sheet
Price: $2.99 +2.05%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE
(Updated - February 17, 2021 7:58 AM EST)

H.C. Wainwright analyst Pat Trucchio initiates coverage on Oncolytics Biotech (NASDAQ: ONCY) with a Buy rating and 415 price target.

The analyst commented, "Oncolytics Biotech, founded in 1998 and based in San Diego, California and Calgary, Alberta, is a biotechnology company focused on developing oncolytic viruses (OVs) for cancer treatment. Oncolytics' lead compound, pelareorep (pela), an unmodified reovirus and first-in-class systemically administered immuno-oncology (I-O) viral agent for solid tumors and hematological malignancies, is on the cusp of demonstrating potential to upend the treatment paradigms of several cancers, in our view. OVs are a group of viruses that infect and kill cancer cells preferentially to normal tissues; although the OV concept is not new, the field is gaining momentum only recently as advancements in technology have made it feasible to thoroughly study viruses and analyze the safety and antitumor efficacy. Oncolytics is evaluating pela in various combination trials in co-development or combination collaborations with Roche, Merck, Pfizer, Incyte, and Bristol-Myers Squibb. We believe it is the studies being conducted in breast cancer (BrCa) that could generate substantial value for shareholders in 2021 and beyond. Hence, we initiate coverage of Oncolytics with a Buy and $15 price target."

For an analyst ratings summary and ratings history on Oncolytics Biotech click here. For more ratings news on Oncolytics Biotech click here.

Shares of Oncolytics Biotech closed at $3.03 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright